Teriparatide Cinnagen (teriparatide)
Biosimilar
- Region
- 🇪🇺 EU
- Active substance
- teriparatide
- Company
- CinnaGen Co Unipessoal LDA
- Status
- Application withdrawn
- Therapeutic area
- Osteoporosis; Osteoporosis, Postmenopausal
- Designations
- Biosimilar
- Application
- EMEA/H/C/005543
- ATC
- H05AA02
- Official record
- www.ema.europa.eu
Indication
Treatment of osteoporosis
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Yorvipath Authorised · Ascendis Pharma Bone Diseases A/S
- 🇪🇺 Kauliv Authorised · Strides Pharma (Cyprus) Limited
- 🇪🇺 Zandoriah Authorised · CinnaGen Co Unipessoal LDA
- 🇪🇺 Terrosa Authorised · Gedeon Richter Plc.
- 🇪🇺 Movymia Authorised · STADA Arzneimittel AG
- 🇪🇺 Sondelbay Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Forsteo Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Livogiva Authorised · Theramex Ireland Limited
- 🇪🇺 Teriparatide Sun Authorised · Sun Pharmaceutical Industries Europe B.V.
- 🇪🇺 Teriparatide Ascend Application withdrawn · Ascend GmbH
- 🇪🇺 Qutavina Withdrawn · EuroGenerics Holdings B.V.
- 🇪🇺 Sondelbay Application withdrawn · Accord Healthcare S.L.U.
Follow Teriparatide Cinnagen
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.